PURPLE TRANSLATIONAL PLATFORM
PANCREATIC CANCER: UNDERSTANDING ROUTINE PRACTICE & LIFTING END RESULTS

Pancreatic cancer trials open to recruitment – September 2025

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

NOTE: Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures
Metastatic	The pancreatic cancer has spread to other parts of the body

PANCREATIC CANCER TRIALS IN VICTORIA
(Trials with specific cohorts for pancreatic cancer)

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
NeoFOL-R Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre Randomized, controlled trial (NeoFOL-R) - Australian protocol	**N/A**	**RESECTABLE** Exclusion: Borderline resectable Locally advanced Previous treatment for pancreatic cancer	mFOLFIRINOX chemotherapy Arm A: Surgery then 12 cycles of chemotherapy Arm B: 6 cycles of chemotherapy before surgery followed by 6 of cycles after surgery Further information: NeoFOL-R - Victorian Cancer Trials Link	Epworth Health	EHJreissatiCentre@epworth.org.au
				Monash Health	gi.oncresearch@monashhealth.org
				Alfred Health	act-m@alfred.org.au
				Western Health	CancerClinicalTrials@wh.org.au
DIRECT-InspIRE Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy	**N/A**	**UNRESECTABLE (Stage 3)** Inclusion: 3 months of chemotherapy (FOLFIRINOX or Gemcitabine based – 1 line only)	NanoKnife System for Irreversible Electroporation (IRE) IRE is a technique using non-thermal energy to create permanent nanopores in the cell membrane in order to disrupt cellular homeostasis. Further information: DIRECT/InspIRE Australia - Victorian Cancer Trials Link	Peter MacCallum Cancer Centre	SurgicalResearchteam@petermac.org
				Alfred Health	charles.pilgrim@monash.edu
				Epworth Health	EHJreissatiCentre@epworth.org.au

PANCREATIC CANCER TRIALS IN VICTORIA
(Trials with specific cohorts for pancreatic cancer)

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
AMG193 20230223 A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223	**MTAP deletion**	**METASTATIC/LOCALLY ADVANCED** *(First line)* Inclusion: Pancreatic cancer Homozygous MTAP-deletion Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	AMG 193 AMG 193 is a PMRT5 inhibitor which is administered orally. AMG 193 will be administered with chemotherapy. Further information: https://trials.cancervic.org.au/details/vctl_nct06360354	Peter MacCallum Cancer Centre Austin Health Epworth Health	PCCTU.MoncC@petermac.org samantha.chakar@austin.org.au EHjreissaticentre@epworth.org.au
Clarity-PT01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	**CLDN18.2**	**METASTATIC/LOCALLY ADVANCED** *(First line)* Inclusion: Pancreatic cancer Treatment naïve CLDN18.2 positive Exclusion: Exposure to prior CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody	AZD0901 (antibody-drug conjugate) AZD0901 targets and binds to CLDN18.2, which is a protein on tumour cells, and then delivers cytotoxic agents which damage these cancer cells. Further information: https://trials.cancervic.org.au/details/vctl_nct06219941	Peter MacCallum Cancer Centre	PCCTU.MoncC@petermac.org
AMPLICITY (AMP945-202) A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	**FAK**	**METASTATIC/LOCALLY ADVANCED** *(First line)* Inclusion: Treatment naïve for metastatic disease	Narmafotinib Narmafotinib is an oral FAK inhibitor. Narmafotinib will be administered in combination with mFOLFIRINOX chemotherapy Further information:	Epworth	EH- PancreaticCentre@epworth.org.au

PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
			https://pancreaticcentre.org.au/treatment/clinical-trials-and-research/amplicity		
FMT Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	**N/A**	**METASTATIC/LOCALLY ADVANCED** *(First line)* Inclusion: Pancreatic cancer Treatment naïve (first line) Exclusion: Antibiotic use within 8 weeks of randomisation (1 dose with ERCP allowed)	Fecal Microbiota Transplantation Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt	Epworth	EH- PancreaticCentre@epworth.org.au
PemOla A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/ Mb	**dMMR/MSI-high** or **TMB > 4 mutations / Mb**	**METASTATIC/LOCALLY ADVANCED** *(First and second line)* Inclusion: Pancreatic cancer ****Awaiting opening date****	Pembrolizumab and Olaparib Pembrolizumab in anti-PD1 antibody Olaparib is a PARP inhibitor Further information: Contact trials unit Expected to open imminently	Monash Health	Gi.oncresearch@monashhealth.org

PANCREATIC CANCER TRIALS IN VICTORIA
(Trials with specific cohorts for pancreatic cancer)

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
LuMIERE A Phase 1/2, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumour	**FAP**	**METASTATIC/LOCALLY ADVANCED** *(First and second line)* Inclusion: Pancreatic ductal adenocarcinoma + other cancers Monotherapy Cohort: Received at least 1 but no more than 2 lines of chemotherapy Combination cohort: Chemotherapy naïve for advanced disease Exclusion: Active CNS disease	[177Lu]Lu-FAP-2286 [177Lu]Lu-FAP-2286 is a radiopharmaceutical that targets fibroblast activation protein (FAP). This treatment works by binding to the FAP to allow the targeted delivery of radiation directly to FAP-expressing cancer cells. [177Lu]Lu-FAP-2286 with or without chemotherapy Further information: https://trials.cancervic.org.au/details/vctl_nct04939610	Alfred Hospital Peter MacCallum Cancer Centre	act-m@alfred.org.au PCCTU.MoncC@petermac.org
Porcupine P2EA An open-label study to assess the preliminary efficacy and safety of RXC004, (Zamaporvint), in patients with advanced pancreatic cancer who have progressed following therapy with current standard of care.	**Porcupine**	**METASTATIC/LOCALLY ADVANCED** *(Second line)* Inclusion: Progression on first line treatment for incurable disease Mandatory biopsy at enrolment	Zamaporvint Zamaporvint is an oral porcupine inhibitor. Treatment will be administered with denosumab Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/porcupine-p2ea	Epworth	EH-PancreaticCentre@epworth.org.au
PAUF-I A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability,	**PAUF**	**METASTATIC/LOCALLY ADVANCED** *(Second line +)* Inclusion:	PBP1510 PBP1510 is an IgG1 monoclonal antibody (mAb) that targets and neutralises PAUF.	Monash Health	earlyphase.oncresearch@monashhealth.org

PANCREATIC CANCER TRIALS IN VICTORIA
(Trials with specific cohorts for pancreatic cancer)

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer		Received at least 1 line of chemotherapy and progressed	Further information: https://trials.cancervic.org.au/details/vctl_nct05141149		
ALAFOSS-01 A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)	**KRAS G12D**	**METASTATIC/LOCALLY ADVANCED** *(Second line +)* Inclusion: KRAS G12D mutation At least one prior line of treatment Exclusion: Prior KRAS inhibitor	AZD0022 AZD0022 is an oral KRAS G12D inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06599502	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
INCB161734 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	**KRAS G12D**	**ADVANCED OR METASATIC SOLID CANCERS** *(Second line +)* Inclusion: Second line and beyond	INCB161734 INCB161734 in a KRAS G12D inhibitor Further information: https://trials.cancervic.org.au/details/vctl_nct06179160	Alfred Health	act-m@alfred.org.au
AMG 410 A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors	**KRAS**	**ADVANCED OR METASATIC SOLID CANCERS** *(Exhausted standard of care)* Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in part 2.	AMG 410 AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab Further information: https://trials.cancervic.org.au/details/vctl_nct07094113	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org

PANCREATIC CANCER TRIALS IN VICTORIA
(Trials with specific cohorts for pancreatic cancer)

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
ELK1004-101 A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors	**HRR deficiency**	**METASTATIC/LOCALLY ADVANCED** *(Second line +)* Inclusion: Suspected deleterious mutation of select HRR genes Exclusion: Prior PARP1 inhibitor	EIK1004 EIK1004 is an oral PARP1 inhibitor and will be administered as monotherapy Further information: https://trials.cancervic.org.au/details/vctl_nct06907043	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
ENG19 An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial)	**EGFR**	**METASTATIC/LOCALLY ADVANCED** *(Third line +)* Inclusion: Progressed on second line or treatment exhausted EGFR expression on local IHC or liquid biopsy	E-EDV-D682/GC E-EDV-D682/GC is a combination of a EnGelC Dream Vector (EDV) transporting the cytotoxic drug PNU-159682 to cells expressing EGFR and an EDV carrying alpha-galactoslyceramide (EDV-GC). Further information: https://trials.cancervic.org.au/details/vctl_actrn12625000203459	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
AMG410 A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants	**KRAS**	**ADVANCED OR METASATIC SOLID CANCERS** *(Exhausted standard of care)* Inclusion: KRAS mutation or amplification	AMG410 AMG410 is an oral KRAS inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct07094113	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org

PANCREATIC CANCER TRIALS IN VICTORIA **(Trials with specific cohorts for pancreatic cancer)**					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
With KRAS Altered Advanced or Metastatic Solid Tumors					

PURPLE TRANSLATIONAL PLATFORM

PANCREATIC CANCER: UNDERSTANDING ROUTINE PRACTICE & LIFTING END RESULTS

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
ADCE-T02-001 First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	**Tissue Factor (TF)**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available Exclusion: Active CNS disease	AMT-754 AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted treatment directly into the cell. Further information: https://trials.cancervic.org.au/details/vctl_nct06597721	Cabrini Peninsula and South Eastern Haematology and Oncology Group	clinicaltrials@cabrini.com.au ag@paso.com.au
HERTHENA A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	**Her3**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: Received 1 line of systemic therapy and progressed Exclusion: Prior anti-Her3 treatment Prior irinotecan	HER3-DXd HER3-DXd is a Her3 antibody-drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct06172478	Monash Health	gi.oncresearch@monashhealth.org
PRT7732-01 A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation	**SMARCA4**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: SMARCA4 mutation Exclusion: Concomitant SMARCA2 mutation	PRT7732 PRT7732 is an oral SMARCA2 degrader. Further information: A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation - Rare Cancers Australia	Monash Health	earlyphase.oncresearch@monashhealth.org

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
HM-EZHI A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	**SWI/SNF Complex aberration (ARID1A SMARCA4 SMARCA2)**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: SW/SNF Complex aberration (ARID1A, SMARCA4, SMARCA2) Exclusion: Prior valemetostat or other EZH1/2 inhibitor use	HM97662 HM97662 is an oral medication (EZH1/2 dual inhibitor). Further information: https://trials.cancervic.org.au/details/feed-cta-trial541	Monash Health	earlyphase.oncresearch@monashhealth.org
				Peninsula and Southeast Oncology	ag@paso.com.au
				Grampians Health (Ballarat)	clinicaltrials@gh.org.au
BGB 58067 A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	**MTAP loss**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: MTAP loss (pre-screening available) Exclusion: Prior treatment with PRMT5 or MAT2A inhibitor	BGB-58067 BGB-58067 is an MTA-Cooperative PRMT5 inhibitor. Further information: NCT06589596 - Victorian Cancer Trials Link	Monash Health *(Note: Austin Health is only recruiting GBM)*	earlyphase.oncresearch@monashhealth.org
BGB 53038 A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of	**KRAS mutation or amplification (excluding**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: Evidence of KRAS mutation or wild-type amplification	BGB-53038 BGB-53038 is a pan-KRAS inhibitor.	Monash Health	earlyphase.oncresearch@monashhealth.org

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications	**KRAS G12R)**	Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment	Further information: NCT06585488 - Victorian Cancer Trials Link	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
YL211 YL211-INT-101-01: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	**cMET**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: No further standard treatment options available	YL211 YL211 is a C-MET targeted antibody-drug conjugate (ADC) available for all tumour types for dose escalation where there is either a C-met aberration or where there is a biological rationale for C-met directed therapy. Further information: YL211-INT-101-01 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monashhealth.org
MK-1084 A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors	**KRAS G12C**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: KRAS G12C mutation	MK1084 MK1084 is an oral KRAS G12C inhibitor. Further information: MK-1084 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monashhealth.org

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
PRIMROSE A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	**MTAP deficient**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: At least 1 prior line of treatment and exhausted treatment options Archival or baseline tumour sample for MTAP testing Exclusion: Prior PRMT5 inhibitor	AZD3470 AZD3470 is a novel, potent and selective second-generation PRT5 inhibitor. Further information: PRIMROSE - Victorian Cancer Trials Link	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
CS5001 A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination with Systemic Therapies in Patients with Advanced Solid Tumors and Lymphomas.	**ROR1**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: Progression on at least 1 prior line of systemic therapy ECOG 0-1	CS5001 CS5001 in an antibody drug conjugate targeting ROR1 Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/cs5001	Epworth	connie.barlas@epworth.org.au or EH-PancreaticCentre@epworth.org.au
MarkV A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309	**VISTA**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Progressed on available prior lines of therapy	PMC-309 PMC-309 is an anti-VISTA monoclonal antibody PMC-309 will be administered	Grampians Health (Ballarat)	clinicaltrials@gh.org.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
(Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors		Progressed on PD-1 or PD-L1 inhibitor immunotherapy Exclusion: Prior anti-VISTA therapy	alone or in combination with pembrolizumab Further information: https://trials.cancervic.org.au/details/vctl_nct05957081	Cabrini	clinicaltrials@cabrini.com.au
BGB-C354-101 Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumours	**B7H3**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Advanced or metastatic solid organ malignancy not amenable to curative intent treatment Exclusion: History of ILD	BGB-C354 BGB-C354 is a B7H3 antibody-drug conjugate Patients are treated with or without tislelizumab (anti-PD1 antibody) Further information: https://clinicaltrials.gov/study/NCT06422520	St Vincents Melbourne	OncologyTrialCoordinators@svha.org.au
AT-0174-001 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	**IDO1/TDO2**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Progressed on available prior lines of therapy	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2 Further information: https://trials.cancervic.org.au/details/vctl_actrn12623000956606	Grampians Health (Ballarat)	clinicaltrials@gh.org.au
				St Vincent's Hospital Melbourne	OncologyTrialCoordinators@svha.org.au

PURPLE TRANSLATIONAL PLATFORM

PANCREATIC CANCER: UNDERSTANDING ROUTINE PRACTICE & LIFTING END RESULTS

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
IMPARP An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects	**HRD deficiency**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second line and beyond Molecular testing within 12 months Confirmed germline or somatic alteration in homologous recombination related gene	Pamiparib and tiselizumab Pamiparib is a PARP1/2 inhibitor. Tislelizumab is an anti-PD1 antibody. Further information: https://trials.cancervic.org.au/details/feed-cta-trial389	Western Health	CancerClinicalTrials@wh.org.au
AKTive-001 A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation	**AKT E17K mutation**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted standard of care therapies Exclusion: Prior mTOR or PI3K inhibitors Presence of KRAS, NRAS, HRAS or BRAF genomic alterations	ALTA2618 ALTA2618 is an oral AKT E17K inhibitor Further information: https://trials.cancervic.org.au/details/vctl_nct06533059	Cabrini	clinicaltrials@cabrini.com.au
AMT-676-01 First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	**CDH17**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second or later line therapy	AMT-676 AMT-676 is an anti-CDH17 antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct06400485	Cabrini	clinicaltrials@cabrini.com.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
D3S-001-100 A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	**KRAS G12C**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: KRAS G12C mutation *Note pancreatic specific cohort has closed. Pantumour cohort remains open with limited slots	D3S 001 D3S 001 is a KRAS G12C inhibitor Further information: https://trials.cancervic.org.au/details/feed-cta-trial449	Cabrini Peter MacCallum Cancer Centre	clinicaltrials@cabrini.com.au PCCTU.EDD@petermac.org
S095035 A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	**MAT2A** **MTAP**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Homozygous deletion of MTAP Second line and beyond	S095035 S095035 is an oral MAT2A inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06188702	Alfred Health	act-m@alfred.org.au
KEYNOTE-F49 A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1	**LILRB1** **LILRB2** **KIR3DL1** ***PD-1***	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second or later line	IOS-1002 +/- Pembrolizumab IOS-1002 binds to LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on innate and adaptive immune cells that suppress immune responses when activated. Pembrolizumab in anti-PD1 antibody.	Bendigo Health	cancerresearch@bendigohealth.org.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
Monoclonal Antibody in Advanced Solid Tumors			Further information: *https://trials.cancervic.org.au/details/feed-cta-trial528*		
SYLVER A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)	**WRN dMMR MSI-h**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second or later line/exhausted treatment options	GSK4418959 +/-PD-1 inhibitor GSK4418959 is an oral WRN-inhibitor. This is given as monotherapy or in combination with a PD-1 inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06710847	Peter MacCallum Cancer Centre	PCCTU.MoncB@petermac.org
GDC-7035 A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation	**KRAS G12D**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: KRAS G12D mutation	GDC-7035 GD-7035 is a KRAS G12D inhibitor. Treatment will be monotherapy or in combination with other anti-cancer treatments. Further information: https://trials.cancervic.org.au/details/vctl_nct06619587	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
RO7566802 A Phase I, Open-Label, Multicenter, Dose-Escalation	**αvβ8 integrin**	**ADVANCED OR METASATIC SOLID CANCERS**	RO7566802 RO7566802 is a αvβ8 integrin inhibitor delivered intravenously.	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors		Inclusion: Second or later line	Further information: https://trials.cancervic.org.au/details/vctl_nct06031441		
MK-6837-001 A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors	**TROP2**	**ADVANCED OR METASATIC SOLID CANCERS** Exclusion: Uncontrolled HIV, Hepatitis B or C	MK-6837 +/- pembrolizumab MK-6837 is a TROP2-MMAE antibody-drug conjugate delivered as monotherapy or in combination with PD-1 inhibitor pembrolizumab. Further information: https://trials.cancervic.org.au/details/vctl_nct06460961	Alfred Health	act-m@alfred.org.au
BG-C477 A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors	**CEACAM5**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: CEA >5	BG-C477 BG-C477 is an antibody-drug conjugate targeting CEACAM5. BG-C477 will be delivered as monotherapy or in combination with capecitabine and bevacizumab. Further information: https://trials.cancervic.org.au/details/vctl_nct06596473	Alfred Health	act-m@alfred.org.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
AMT-562-01 First-in-Human, Phase 1 Study of AMT-562, an Anti HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	**HER3**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second line and beyond	AMT-562 AMT-562 is a novel HER3 targeting antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct06199908	Cabrini	clinicaltrials@cabrini.com.au
SNT1521 A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors	**PARP**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted treatment options	SNT1521 SNT1521 is a PARP1 inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06220864	Monash Health	earlyphase.oncresearch@monashhealth.org
MYE-Symphony/MTX-TROP2-302 A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors	**TROP2**	**ADVANCED OR METASATIC SOLID CANCERS**	MT-302 MT-302 is an anti-TROP2-CD89 mRNA CAR therapy. Further information: MYE Symphony - Victorian Cancer Trials Link	Cabrini	clinicaltrials@cabrini.com.au
IKSUDA A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic	**HER2**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: HER2 IHC 1-3+ HER2 ISH negative and positive	IKS014 IKS014 is a HER2 targeting antibody drug conjugate. Further information:	Peninsula and Southeast Oncology	ag@paso.com.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors			https://trials.cancervic.org.au/details/vctl_nct05872295		
LOXO-RAS-200001 A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	**KRAS G12C**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: KRAS G12C mutation	LY3537982 LY3537982 is a KRAS G12C inhibitor and will be administered as monotherapy or in combination with other systemic anticancer medications. Further information: https://trials.cancervic.org.au/details/vctl_nct04956640	Peninsula and Southeast Oncology	ag@paso.com.au
Stingray SR-8541A-001 Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors	**ENPP1**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment	SR-8541A SR-8541A is an ENPP1 inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06063681	Peninsula and Southeast Oncology	ag@paso.com.au
BAY3498264 Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	**SOS1** **KRAS**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: KRAS G12C mutation	BAY3498264 BAY3498264 is a SOS1 inhibitor. Treatment will be in combination with sotorasib. Further information: https://trials.cancervic.org.au/det	Peninsula and Southeast Oncology	ag@paso.com.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
			ails/vctl_nct06659341		
AK138D1 A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	**HER3**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment	Patritumab Deruxtecan Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate Further information: https://trials.cancervic.org.au/details/vctl_nct06730386	Peninsula and Southeast Oncology	ag@paso.com.au
DT-7012-CLI-001 Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)	**CCR8**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Second or later line	DT-7012 DT-7012 is an anti-CCR8 antibody. Further information: https://clinicaltrials.gov/study/NCT06819735	Peninsula and Southeast Oncology	ag@paso.com.au
SNV4818 A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors	**PIK3CA**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Activating PIK3CA mutation Exhausted conventional treatment *Note: Pantumour for dose escalation cohorts*	SNV4818 SNV4818 is an oral PI3Kα inhibitor. SNV4818 will be delivered with or without fulvestrant Further information: NCT06736704 - Victorian Cancer	Monash Health	earlyphase.oncresearch@monashhealth.org
CS2009 A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate	**dMMR TMB-H HRD phenotype**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion:	CS2009 CS2009 is a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4.	Monash Health	earlyphase.oncresearch@monash

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants With Advanced Solid Tumors		Exhausted conventional treatment *Note: PDAC considered but other tumour types preferred* *Molecular profile taken into account (i.e. dMMR, TMB-H)*	CS2009 will be given IV every 3 weeks Further information: CS2009 - Victorian Cancer Trials Link		health.org
BM230 A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors	**HER2**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: HER2 1+ expression	BM230 BM230 is delivered subcutaneously each week for 3 weeks followed by fortnightly administration Further information: BM230 - Victorian Cancer Trials	Monash Health	earlyphase.oncresearch@monash health.org
BT317 A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients with Advanced Solid Tumors		**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment	BT317 BT317 is administered intravenously Further information: NCT06750185 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monash health.org

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
OZ-001-101 A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer	**STAT3**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment Confirmed accepting PDAC for phase 1a	OZ-001 OZ-001 is a small molecule dual inhibitor of the STAT3 and T-type calcium channels Further information: https://trials.cancervic.org.au/details/vctl_actrn12625000163404	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
INI-4001-101 An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients with Advanced Solid Tumours	**TLR7/8**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment Pre-screening component (review of medical history) *Minimal slots available	INI-4001 INI-4001 is TLR7/8 agonist. Further information: https://trials.cancervic.org.au/details/vctl_nct06302426	Cabrini	clinicaltrials@cabrini.com.au
LM350-01-10 A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients with Advanced Solid Tumors	**CDH17**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment	LM350 LM350 is a CDH17 targeted antibody drug conjugate Further information: https://clinicaltrials.gov/study/NCT07112222?aggFilters=status:not	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au

SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
RO7673396 A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)	**RAS**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Exhausted conventional treatment Confirmed presence of RAS mutation	RO7673396 RO7673396 is an oral RAS inhibitor Further information: https://trials.cancervic.org.au/details/vctl_nct06884618	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org

SUPPORTIVE CARE TRIALS FOR PATIENTS WITH PANCREATIC CANCER IN VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
DINE-PC Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC)	**N/A**	**ALL STAGES OF PANCREATIC CANCER**	Dietetics counselling Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc	Epworth	EH-PancreaticCentre@epworth.org.au

Phase 1 Trials are offered in Victoria at the following locations:

Study Site	Contact	Email	Phone
Alfred Hospital (Prahran VIC 3004)	Clinical Trial Team	moncACT1@alfredhealthconnect.onmicrosoft.com	TBA
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	samantha.chakar@austin.org.au	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	cstu.manager@barwonhealth.org.au	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	rwoods@cabrini.com.au	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	ehjreissaticentre@epworth.org.au	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	ag@paso.com.au	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	earlyphase.oncresearch@monashhealth.org	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	clinicaltrials.enquiries@petermac.org	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	oncology.research@svha.org.au	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	CancerClinicalTrials@wh.org.au	03 83959136 or 0434915739

For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.

PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
MT302 A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT–302 in Adults with Advanced or Metastatic Epithelial Tumors	**TROP2**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy. *Note: closed to pancreas at some centres.	MT302 MT302 is an anti-TROP2-CD89 mRNA CAR therapy Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13719	Scientia Clinical Research (NSW) Westmead Hospital (NSW) Linear Clinical Research LTD Nedlands (WA)	adrian.talarico@scientiaclinicalresearch.com.au meenal.rai@health.nsw.gov.au enquiries@linear.org.au
CA233-0000/ BMS-986484 A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors	**CD40/FAP**	**ADVANCED OR METASTATIC SOLID CANCERS** Exclusion: History of ILD	BMS-986484 BMS-986484 (a CD40/FAP bispecific agonist) is delivered as monotherapy or in combination with nivolumab	St Vincent's Hospital Darlinghurst (NSW) Lyell McEwin Hospital	svhs.research@svha.org.au Health.NALHNCancerResearch@sa.gov.au

PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
				(SA)	
Clarity-PT01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	**CLDN18.2**	**METASTATIC/LOCALLY ADVANCED** Inclusion: Pancreatic cancer Treatment naïve (first line) CLDN18.2 positive Exclusion: Exposure to prior CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody	AZD0901 (antibody-drug conjugate) AZD0901 targets and binds to CLDN18.2, which is a protein on tumour cells, and then delivers cytotoxic agents which damage these cancer cells. Further information: **https://www.anzctr.org.au/TrialSearch.aspx#&&searchTxt=NCT06219941**	Prince of Wales Hospital (NSW)	SESLHD-POW- CTRUreferrals@health.nsw.gov.au
				Fiona Stanley Hospital (WA)	Chia.Tan@health.wa.gov.au
AMG193 20230223 A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223	**MTAP deletion**	**METASTATIC/LOCALLY ADVANCED** Inclusion: Pancreatic cancer Homozygous MTAP-deletion Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	AMG 193 AMG 193 is a PMRT5 inhibitor which is administered orally. AMG 193 will be administered with chemotherapy. Further information: https://www.genesiscare.com/au/clinical-trials/listings/amg-193-20230223	Genesis Care Norths Shore (NSW)	admin.northshore@genesiscare.com

PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
AMPLICITY (AMP945-202) A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	**FAK**	**METASTATIC/LOCALLY ADVANCED** *(First line)* Inclusion: Treatment naïve for metastatic disease	Narmafotinib Narmafotinib is an oral FAK inhibitor. Narmafotinib will be administered in combination with mFOLFIRINOX chemotherapy Further information: AMPLICITY Trial	Genesis Care Norths Shore (NSW)	admin.northshore@genesiscare.com
VVD-130850-001 A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.	**STAT3**	**ADVANCED OR METASTATIC SOLID CANCERS** ****STUDY ON HOLD****	VVD130850 VVD130850 is a novel STAT3-inhibitor. Treatment will be as a monotherapy or in combination with checkpoint inhibition (pembrolizumab) Further information: https://clinicaltrials.gov/study/NCT06188208?term=NCT06188208&rank=1	Central West Cancer Care Centre (Orange Hospital NSW)	bernadette.sheldon@health.nsw.gov.au
				Blacktown Cancer & Haematology Centre (NSW)	raymond.tangunan@health.nsw.gov.au
				Cancer Research South Australia (SA)	admin@crsa.au
				Gold Coast	CBDclinicaltrials@health.qld.gov.a

PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
				University Hospital (QLD)	u
				ICON Cancer Research (South Brisbane QLD)	admin.southbrisbane@icon.team
ALKOVE-1 A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL–to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE–to1)	**ALK**	**ADVANCED OR METASTATIC SOLID CANCERS** Inclusion: ALK rearrangement or activating ALK mutation	NVL655 NVL655 (neladalkib) is an oral selective ALK inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595	Royal North Shore Hospital NSW	PI: malinda.itchins@sydney.edu.au Trial coordinator: shirley.liang@health.nsw.gov.au
AT-0174-001 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	**IDO1/TDO 2**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Progressed on available prior lines of therapy	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2 Further information: https://www.anzctr.org.au/Trial	Royal North Shore Hospital (NSW)	PI: helen.wheeler@health.nsw.gov.au Trial Coordinator: wenqiong.yu@health.nsw.gov.au

PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
BGB-58067 A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	**MTAP deficiency**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion: Any treatment line	BGB-58067 BGB-58067 is a PMRT5 inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130	Blacktown Cancer & Haematology Centre (NSW)	William.dAvigdor@health.nsw.gov.au
GeneScreen 5FU DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	**DPYD**	**SOLID CANCERS – ALL STAGES** Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy Exclusion: Prior FP containing chemotherapy prior to study entry.	DPYD genotyping Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy Further information: ANZCTR - Registration	Lake Macquarie Private Hospital (NSW)	ClinicalTrialsUnit.LMP@ramsayhealth.com.au
				Fiona Stanley Hospital (WA)	audrey.margery-Muir@health.wa.gov.au
INCB161734 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	**KRAS G12D**	**ADVANCED OR METASATIC SOLID CANCERS** *(Second line +)* Inclusion: Second line and beyond	INCB161734 INCB161734 in a KRAS G12D inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14020	St Vincent's Hospital Darlinghurst (NSW)	robert.kent@svha.org.au

PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients.	**NA**	**METASTATIC/LOCALLY ADVANCED** Inclusion: Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma	Metronomic capecitabine, oxaliplatin and UGT1A1 genotype directed irinotecan Further information: https://clinicaltrials.gov/study/NCT05929885?term=NCT05929885&rank=1b	National Cancer Centre Singapore	honey.shwe.sin@nccs.com.sg
A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	**MTAP loss**	**ADVANCED OR METASATIC SOLID CANCERS** Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	BAY 3713372 BAY 3713372 is a novel 2nd generation PRMT5 inhibitor. Further information: https://clinicaltrials.gov/study/NCT06914128	National Cancer Centre Singapore	Wang.jue.lynn@nccs.com.sg
A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors with a KRAS G12D mutation	**KRAS G12D**	**METASTATIC/LOCALLY ADVANCED** Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma	GDC-7035 GDC-7035 is a KRAS G12D inhibitor	National Cancer Centre Singapore	Ye.xin@nccs.com.sg

PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	**Targets (Genomic)**	**Target population** *(Trial suitable for patients with this stage of pancreatic cancer)*	**Treatment + Further Information** *(What the study involves)*	**Site** *(Where the study is being offered)*	**Contact Details** *(Email the contact person listed with any enquiries)*
PAUF-I A first in human phase I/2A, multicentre, open label study of evaluating the safety, tolerability, pharmacokinetics, and efficacy of PBP1510 in patients with advanced/metastatic pancreatic cancer	**PAUF**	**METASTATIC/LOCALLY ADVANCED** Inclusion: Systemic Treatment exposed pancreatic adenocarcinoma	PBP 1510 PBP 1510 is an anti-PAUF antibody Further information: https://clinicaltrials.gov/study/NCT05141149	National Cancer Centre Singapore	Goh.mui.leng@singhealth.com.sg